To The Moon

• OncoCyte Corp OCX.OQ reported a quarterly adjusted loss of 98 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -81 cents. The mean expectation of three analysts for the quarter was for a loss of 44 cents per share. Wall Street expected results to range from -47 cents to -40 cents per share.

• Revenue fell 73.2% to $115.00 thousand from a year ago; analysts expected $200.00 thousand.

• OncoCyte Corp's reported EPS for the quarter was a loss of 98 cents​.

• The company reported a quarterly loss of $13.49 million.

• OncoCyte Corp shares had risen by 5.3% this quarter and gained 20.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 22.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for OncoCyte Corp is 4.13

This summary was machine generated from LSEG data November 13 at 02:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)